
A newly released observational analysis found that 84.4% of cancer patients treated off-label with a compounded combination of Ivermectin and Mebendazole experienced a clinical benefit.
Key Takeaways
Right-leaning
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Right-leaning desks have 1 source on "Ivermectin + Mebendazole: Groundbreaking Study Reports 84.4% Clinical Benefit Rate in Cancer Patients"; additional angles may appear as coverage expands.
Get every side of the week's biggest story in your inbox.
Evaluated across 1 reporting source (0% Left · 0% Center · 100% Right)
Historical editorial baseline for Breitbart
Multi-factor accuracy index for Breitbart and related desks based on verifiable sourcing and editorial standards.
Factuality: High 0%
Ownership: Breitbart (Corporate)
Public conversation related to this story
Loading comments…